Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480)
South Korea · Delayed Price · Currency is KRW 7,060.00
+40.00 (0.57%)
At close: Jan 23, 2026
KOSDAQ:036480 Revenue
Daesung Microbiological Labs. had revenue of 7.18B KRW in the quarter ending September 30, 2025, with 23.50% growth. This brings the company's revenue in the last twelve months to 25.86B, up 7.02% year-over-year. In the year 2024, Daesung Microbiological Labs. had annual revenue of 23.80B, down -6.88%.
Revenue (ttm)
25.86B
Revenue Growth
+7.02%
P/S Ratio
1.04
Revenue / Employee
193.00M
Employees
134
Market Cap
26.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.80B | -1.76B | -6.88% |
| Dec 31, 2023 | 25.56B | 62.26M | 0.24% |
| Dec 31, 2022 | 25.50B | 1.50B | 6.26% |
| Dec 31, 2021 | 24.00B | -803.74M | -3.24% |
| Dec 31, 2020 | 24.80B | -332.95M | -1.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 95.37B |
| GeneBioTech Co. ,Ltd | 92.28B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |
| WooGene B&G | 54.77B |
| Seoul Pharma | 52.43B |
| Union Korea Pharm | 33.83B |
| BIFIDO | 18.65B |
| HLscience | 18.10B |